InflaRx N.V.

General information
InflaRx N.V.
Winzerlaer Str. 2
07745 Jena, Thuringia

Contact person: Niels C. Riedemann, Chief Executive Officer, Board Executive Director
Company main phone: +49 (3641) 508180
Company main fax:  +49 (3641) 508181
Year founded:2007
Source of foundation:Independent foundation
No. of employees: Worldwide:  62
Corporate description / mission:
InflaRx is a clinical-stage biopharmaceutical company focused on applying the proprietary anti-C5a technology to discover and develop potent and specific inhibitors of C5a. Complement C5a is a powerful inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. InflaRx’s lead product candidate, vilobelimab, is a novel, intravenously delivered, first-in-class, anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical studies in different indications.
State of ownership: Publicly listed on stock exchange
Headquarters: HQ: Yes
IPO (year): 2017
Remarks on ownership / listings
InflaRx has offices in Jena and Munich, Germany and a research facility in Ann Arbor, Michigan.
  • Biotechnology - Therapeutics and Diagnostics
  • Anti-infectives
  • Antibodies
  • Small molecules
Primary therapeutic areas:
  • Diseases of the blood and blood-forming organs & immune disorders / hematology / immunology
  • Infectious and parasitic diseases / infectiology / parasitology
  • Neoplasms / cancer / oncology
  • Skin and subcutaneous tissue / dermatology
  • Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified
Business model:
  • In-licensing
  • Manufacturer
  • R&D
  • Supplier / Distributor
Customer segments:
  • Hospitals
  • Large biotech & big pharma
  • Physicians / doctors
  • Small biotech
  • Indirect (independent dealer)
Summary Products / Services / Technologies
Number of Biotech Products
Phase I:1
Phase II:1
Phase III:2
On the market:1
Description of products:
Vilobelimab (IFX-1)
Technology used:
Anti C5a Technology
Financing details
Fiscal year (end of) 2023
Revenues:USD 0.07M
R&D expenses:USD 43.48M
Cash:USD 13.83M
Total liabilities:USD 19.09M
No. of shares:58'883'300
Market cap. / valuation:USD 69.48M